secukinumab · Cosentyx

Monoclonal antibody

Also known as AIN457

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Hidradenitis Suppurativa

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (6)
US
  • Ankylosing spondylitis and non-radiographic axial spondyloarthritis, adult and paediatricFDA label
  • Active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and olderOutside this platform's coverageFDA label
Product first approved 2015
CN
  • Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy (Novartis release dated 2019-04-02)
Product first approved 2019novartis.com
EU
  • Moderate to severe plaque psoriasis in adults (first indication); current label includes psoriatic arthritis, ankylosing spondylitis, nr-axSpA, HS, ERA/JPsA
Product first approved 2015EMA
JP
  • Psoriasis vulgaris and psoriatic arthritis in adults not adequately controlled by systemic therapies; first approval worldwide
Product first approved 2014pmlive.com
CA
  • COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for: Adult patients Plaque psoriasis COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Psoriatic arthritis COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. COSENTYX can be used alone or in combination with methotrexate (see 14.1.1 Psoriatic arthritis). Axial...
Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (89)
Hidradenitis Suppurativa
NCT04179175 · Novartis Pharmaceuticals
2020-03-18 – 2026-07-15 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT03668613 · Novartis Pharmaceuticals
2018-08-29 – 2023-09-12 · Moderate to Severe Chronic Plaque-type Psoriasis
What this study did
NCT04237116 · Novartis Pharmaceuticals
2020-02-19 – 2021-07-23 · Plaque Psoriasis, Non-alcoholic Fatty Liver Disease
What this study did
NCT03504852 · Novartis Pharmaceuticals
2018-06-25 – 2020-07-15 · Moderate to Severe Chronic Plaque-type Psoriasis
What this study did
NCT03066609 · Novartis Pharmaceuticals
2017-02-28 – 2018-11-20 · Plaque Psoriasis
What this study did
NCT02826603 · Novartis Pharmaceuticals
2016-06-22 – 2018-07-09 · Plaque Psoriasis
What this study did
NCT01544595 · Novartis Pharmaceuticals
2012-06-19 – 2017-06-26 · Moderate to Severe Plaque-type Psoriasis
What this study did
NCT02008890 · Novartis Pharmaceuticals
2013-12-26 – 2017-05-31 · Palmoplantar Pustular Psoriasis
What this study did
NCT02409667 · Novartis Pharmaceuticals
2015-05-07 – 2017-05-08 · Plaque Psoriasis
What this study did
NCT01640951 · Novartis Pharmaceuticals
2012-09-16 – 2017-05-04 · Moderate to Severe Chronic Plaque-Type Psoriasis
What this study did
NCT02795416 · Novartis Pharmaceuticals
2016-06 – 2017-03 · Psoriasis
What this study did
NCT01807520 · Novartis Pharmaceuticals
2013-06-20 – 2017-01-03 · Moderate to Severe Nail Psoriasis
What this study did
NCT01806597 · Novartis Pharmaceuticals
2013-06-19 – 2016-11-02 · Moderate to Severe Palmoplantar Psoriasis
What this study did
NCT02474069 · Novartis Pharmaceuticals
2015-02-08 – 2016-09-15 · Moderate to Severe Plaque-type Psoriasis
What this study did
NCT02362789 · Novartis Pharmaceuticals
2015-01-04 – 2016-07-15 · Psoriasis
What this study did
NCT01961609 · Novartis Pharmaceuticals
2013-10-09 – 2016-07-12 · Psoriasis
What this study did
NCT02074982 · Novartis Pharmaceuticals
2014-02-26 – 2016-06-29 · Chronic Plaque Type Psoriasis
What this study did
NCT02474082 · Novartis Pharmaceuticals
2015-04 – 2016-06 · Psoriasis
What this study did
NCT02559622 · Novartis Pharmaceuticals
2014-04 – 2016-04 · Psoriasis
What this study did
NCT01952015 · Novartis Pharmaceuticals
2013-08-21 – 2016-03-15 · Psoriasis
What this study did
NCT01406938 · Novartis Pharmaceuticals
2011-08 – 2013-05 · Moderate to Severe Plaque-type Psoriasis
What this study did
NCT01412944 · Novartis Pharmaceuticals
2011-12 – 2013-04 · Plaque-type Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT03769168 · Novartis Pharmaceuticals
2019-06-07 – 2024-11-07 · Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis
What this study did
NCT04711902 · Novartis Pharmaceuticals
2021-06-24 – 2023-03-10 · Psoriatic Arthritis
What this study did
NCT04209205 · Novartis Pharmaceuticals
2020-01-29 – 2022-05-17 · Psoriatic Arthritis
What this study did
NCT02662985 · Novartis Pharmaceuticals
2016-08-22 – 2020-11-10 · Psoriatic Arthritis
What this study did
NCT02745080 · Novartis Pharmaceuticals
2017-04-03 – 2019-12-30 · Psoriatic Arthritis
What this study did
NCT02771210 · Novartis Pharmaceuticals
2016-08-30 – 2019-12-11 · Psoriatic Arthritis, Axial Spondyloarthritis, Enthesitis
What this study did
NCT02721966 · Novartis Pharmaceuticals
2016-10-03 – 2019-06-26 · Axial Psoratic Arthritis
What this study did
NCT01989468 · Novartis Pharmaceuticals
2014-04-10 – 2018-03-28 · Psoriatic Arthritis
What this study did
NCT01892436 · Novartis Pharmaceuticals
2013-09-30 – 2018-01-11 · Psoriatic Arthritis
What this study did
NCT02294227 · Novartis Pharmaceuticals
2015-05-29 – 2017-12-19 · Arthritis, Psoriatic
What this study did
Phase 2 (41)
Psoriasis
NCT03131570 · James G. Krueger, MD, PhD
2017-05-23 – 2021-06-21 · Psoriasis
What this study did
NCT03553823 · Novartis Pharmaceuticals
2019-01-14 – 2020-01-28 · Chronic Plaque-type Psoriasis
What this study did
NCT01132612 · Novartis Pharmaceuticals
2010-05-11 – 2016-10-18 · Plaque-type Psoriasis
What this study did
NCT01537432 · Novartis Pharmaceuticals
2012-01 – 2014-12 · Psoriasis, Plaque-type Psoriasis
What this study did
NCT01071252 · Novartis Pharmaceuticals
2010-03 – 2011-02 · Chronic Plaque-type Psoriasis
What this study did
NCT00941031 · Novartis Pharmaceuticals
2009-07 – 2010-12 · Chronic Plaque-type Psoriasis
What this study did
NCT00805480 · Novartis Pharmaceuticals
2008-12 – 2010-09 · Chronic Plaque Psoriasis
What this study did
NCT00770965 · Novartis Pharmaceuticals
2008-09-10 – 2009-09-17 · Chronic Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT02854163 · University of Liverpool
2016-10-15 – 2019-09-18 · Psoriatic Arthritis
What this study did
NCT02483234 · University of Erlangen-Nürnberg Medical School
2015-05-31 – 2018-09-30 · Psoriasis, Psoriatic Arthritis
What this study did
NCT01169844 · Novartis Pharmaceuticals
2010-06 – 2012-11 · Psoriatic Arthritis
What this study did
NCT00809614 · Novartis Pharmaceuticals
2009-03 – 2010-12 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07477795 · Assistance Publique - Hôpitaux de Paris
2026-04-01 – 2030-04-01 · Takayasu Arteritis, Large Vessel Vasculitis
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT03651518 · Assistance Publique - Hôpitaux de Paris
2020-10-20 – 2025-11-20 · Inflammatory Disease, Autoimmune Diseases
What this study did
NCT04300296 · Novartis Pharmaceuticals
2020-07-27 – 2022-05-03 · Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
What this study did
NCT04274166 · Wake Forest University Health Sciences
2021-05 – 2022-04 · Pyoderma Gangrenosum
What this study did
NCT03866317 · Massachusetts General Hospital
2019-09-01 – 2021-06-30 · Discoid Lupus Erythematosus
What this study did
NCT03765788 · Novartis Pharmaceuticals
2019-01-30 – 2021-06-08 · Giant Cell Arteritis
What this study did
NCT03791060 · Beth Israel Deaconess Medical Center
2019-04-03 – 2021-04-10 · Necrobiosis Lipoidica Diabeticorum
What this study did
NCT03041038 · Northwestern University
2016-12 – 2020-08-31 · Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis, Congenital Ichthyosiform Erythroderma, Epidermolytic Ichthyosis, Netherton Syndrome
What this study did
NCT04403243 · Lomonosov Moscow State University Medical Research and Educational Center
2020-05-08 – 2020-08-23 · COVID 19
What this study did
NCT03344640 · Novartis Pharmaceuticals
2017-12-15 – 2019-10-17 · Tendinopathy
What this study did
NCT02599129 · Icahn School of Medicine at Mount Sinai
2015-11 – 2016-11 · Alopecia Areata
What this study did
NCT01478360 · Novartis Pharmaceuticals
2012-03 – 2014-11 · Asthma
What this study did
NCT02044848 · Novartis Pharmaceuticals
2014-02 – 2014-09 · Type 1 Diabetes Mellitus
What this study did
NCT01433250 · Novartis Pharmaceuticals
2012-02 – 2014-06 · Multiple Sclerosis
What this study did
NCT01874340 · Novartis Pharmaceuticals
2013-06 – 2014-04 · Multiple Sclerosis
What this study did
NCT01426789 · Novartis Pharmaceuticals
2011-08 – 2014-02 · Rheumatoid Arthritis
What this study did
NCT01359943 · Novartis Pharmaceuticals
2011-10 – 2013-12 · Rheumatoid Arthritis
What this study did
NCT00685399 · Novartis Pharmaceuticals
2008-06 – 2013-09 · Non-infectious Uveitis
What this study did
NCT01364389 · Novartis Pharmaceuticals
2011-02-14 – 2013-01-29 · Polymyalgia Rheumatica, Inflammatory Diseases
What this study did
NCT01109940 · Novartis Pharmaceuticals
2010-04 – 2012-12 · Ankylosing Spondylitis
What this study did
NCT01051817 · Novartis Pharmaceuticals
2009-12 – 2012-04 · Relapsing-remitting Multiple Sclerosis, RRMS
What this study did
NCT01250171 · Novartis Pharmaceuticals
2010-11 – 2011-09 · Dry Eye
What this study did
NCT00809159 · Novartis Pharmaceuticals
2009-03 – 2011-05 · Ankylosing Spondylitis
What this study did
NCT00928512 · Novartis Pharmaceuticals
2009-07 – 2011-03 · Rheumatoid Arthritis
What this study did
NCT01009281 · Novartis Pharmaceuticals
2009-10-30 – 2010-08-19 · Crohn's Disease, Inflammatory Bowel Disease
What this study did
NCT00584740 · Novartis Pharmaceuticals
2008-08 – 2010-08 · Crohn's Disease
What this study did
Phase 1/2 (6)
Psoriasis
NCT00669916 · Novartis Pharmaceuticals
2007-02 – 2007-11 · Plaque Psoriasis
What this study did
Other / comorbidity
NCT04298320 · Yanqiao Zhang
2020-03-15 – 2023-02-28 · Colorectal Cancer
What this study did
NCT02733094 · Technical University of Munich
2016-04 – 2019-09-19 · Pyoderma Gangrenosum
What this study did
NCT03079531 · Anne Chang
2017-06-21 – 2019-01-25 · Papulopustular Rosacea
What this study did
NCT00920933 · Novartis Pharmaceuticals
2009-01 – 2009-11 · Healthy
What this study did
NCT00669942 · Novartis Pharmaceuticals
2005-12 – 2008-11 · Rheumatoid Arthritis
What this study did
Phase 1 (13)
Hidradenitis Suppurativa
NCT03099980 · Tufts Medical Center
2016-07-11 – 2019-01 · Hidradenitis Suppurativa
What this study did
Psoriasis
NCT07254325 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2025-12-15 – 2026-06-22 · Psoriasis
What this study did
NCT05734482 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2023-02-15 – 2023-07-03 · Psoriasis
What this study did
NCT04414605 · Guangdong Provincial Hospital of Traditional Chinese Medicine
2020-06-04 – 2021-12-31 · Psoriasis
What this study did
NCT02607774 · Novartis Pharmaceuticals
2015-12-17 – 2016-12-20 · Moderate to Severe Plaque Psoriasis
What this study did
NCT01539213 · Novartis Pharmaceuticals
2012-02 – 2013-01 · Healthy, Psoriasis
What this study did
Psoriatic Arthritis
NCT06751238 · Novartis Pharmaceuticals
2025-09-24 – 2031-03-11 · Juvenile Psoriatic Arthritis
What this study did
NCT04967950 · Peking Union Medical College Hospital
2021-07-15 – 2022-12-31 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07237594 · Duke University
2026-03-12 – 2030-06-30 · Metastatic Melanoma
What this study did
NCT06130540 · Novartis Pharmaceuticals
2024-03-27 – 2025-04-02 · Giant Cell Arteritis, Polymyalgia Rheumatica
What this study did
NCT05522517 · Janssen Research & Development, LLC
2022-08-22 – 2022-11-02 · Healthy
What this study did
NCT03342573 · Mayo Clinic
2018-04-01 – 2022-02-01 · PITYRIASIS RUBRA PILARIS
What this study did
NCT04589026 · Janssen Research & Development, LLC
2020-10-21 – 2021-05-06 · Healthy
What this study did
Phase 4 (37)
Hidradenitis Suppurativa
NCT07489573 · Novartis Pharmaceuticals
2026-06-01 – 2029-11-05 · Hidradenitis Suppurativa (HS)
What this study did
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06398106 · University Hospital, Ghent
2024-12-20 – 2028-03-01 · Psoriasis Vulgaris
What this study did
NCT04239859 · Singapore General Hospital
2024-01 – 2027-12 · Plaque Psoriasis
What this study did
NCT04535999 · University of Pennsylvania
2022-02-07 – 2025-05-30 · Psoriasis
What this study did
NCT04717466 · University of Miami
2021-06-29 – 2025-03-04 · Psoriasis, Healthy
What this study did
NCT04340076 · Radboud University Medical Center
2020-08-20 – 2025-01-31 · Psoriasis, Psoriasis Vulgaris
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT04080661 · University Hospital, Ghent
2018-03-22 – 2023-12-31 · Psoriasis Vulgaris
What this study did
NCT03020199 · Novartis Pharmaceuticals
2017-03-27 – 2023-06-16 · Plaque Psoriasis
What this study did
NCT04469829 · Universita di Verona
2020-08-01 – 2022-12-31 · Psoriasis, Metabolic Syndrome
What this study did
NCT05891964 · Jinnah Postgraduate Medical Centre
2021-07-05 – 2022-07-10 · Plaque Psoriasis
What this study did
NCT04571567 · Saakshi Khattri
2019-12-02 – 2022-02-22 · Psoriasis
What this study did
NCT03307447 · Narrows Institute for Biomedical Research
2017-12-19 – 2021-12 · Psoriasis Vulgaris
What this study did
NCT03055494 · Novartis Pharmaceuticals
2017-04-18 – 2019-02-26 · Plaque Psoriasis
What this study did
NCT02592018 · University of California, San Francisco
2016-10 – 2018-12 · Psoriasis
What this study did
NCT02752776 · Novartis Pharmaceuticals
2016-03-17 – 2018-03-28 · Plaque Psoriasis
What this study did
NCT02690701 · Novartis Pharmaceuticals
2016-02-10 – 2018-02-19 · Chronic Plaque Psoriasis
What this study did
NCT02547714 · Novartis Pharmaceuticals
2015-06-16 – 2016-05-02 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT03623867 · Chinese University of Hong Kong
2020-05-18 – 2022-09-30 · Psoriatic Arthritis
What this study did
NCT04887597 · University of Erlangen-Nürnberg Medical School
2019-03-18 – 2022-09 · Psoriatic Arthritis, Enthesitis, Biopsy
What this study did
NCT04488185 · Novartis Pharmaceuticals
2020-11-02 – 2021-03-24 · Psoriasis
What this study did
Other / comorbidity
NCT04638647 · Novartis Pharmaceuticals
2020-12-22 – 2030-04-04 · Autoimmunity, Inflammation
What this study did
NCT07770646 · The University of Texas Health Science Center, Houston
2026-11-01 – 2029-09-15 · Axial Spondyloarthritis (AxSpA)
What this study did
NCT07704190 · Peking University Third Hospital
2026-07-15 – 2028-12-31 · Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery Disease, Hypertension, Type 2 Diabetes Mellitus, Peripheral Arterial Disease, Carotid Artery Stenosis
What this study did
NCT05622708 · Novartis Pharmaceuticals
2023-03-28 – 2028-04-04 · Non-radiographic Axial Spondyloarthritis
What this study did
NCT06833112 · The Affiliated Hospital Of Guizhou Medical University
2025-02 – 2028-02 · Ankylosing Spondylitis
What this study did
NCT05303285 · Tongji Hospital
2024-06-14 – 2026-08-31 · Ankylosing Spondylitis (AS)
What this study did
NCT05527444 · Qilu Hospital of Shandong University
2022-03-15 – 2024-12-31 · Ankylosing Spondylitis
What this study did
NCT03445845 · Centre Hospitalier Universitaire de Saint Etienne
2018-12-14 – 2024-10-01 · Axial Spondyloarthritis
What this study did
NCT04996485 · National Medical Research Center for Children's Health, Russian Federation
2021-03-01 – 2023-06-01 · Congenital Ichthyosis
What this study did
NCT03350815 · Novartis Pharmaceuticals
2018-03-13 – 2021-05-29 · Ankylosing Spondylitis
What this study did
NCT03639740 · Professor Mikkel Østergaard
2019-01-15 – 2021-02 · Axial Spondyloarthritis, Ankylosing Spondylitis
What this study did
NCT02763046 · Novartis Pharmaceuticals
2016-05-31 – 2019-09-24 · Ankylosing Spondylitis
What this study did
NCT05676333 · University Hospital, Ghent
2016-10-12 – 2019-02-22 · Vitiligo, Secukinumab
What this study did
Early phase / not applicable (2)
Hidradenitis Suppurativa
NCT06707246 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-12-15 – 2027-10 · Hidradenitis Suppurativa
What this study did
Other / comorbidity
NCT00936585 · National Institutes of Health Clinical Center (CC)
2009-07 – 2011-02 · Colitis, Crohn's Disease, Inflammatory Bowel Disease
What this study did
Used as active comparator (15)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Psoriasis
NCT06945107 · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
2025-05-27 – 2027-01-19 · Plaque Psoriasis
What this study did
NCT06630559 · Celltrion
2025-05-26 – 2026-10 · Plaque Psoriasis
What this study did
NCT06398652 · Taizhou Mabtech Pharmaceutical Co.,Ltd
2024-08-27 – 2026-03-19 · Psoriasis
What this study did
NCT06110676 · Livzon Pharmaceutical Group Inc.
2023-08-21 – 2025-06 · Psoriasis
What this study did
NCT05377944 · Bio-Thera Solutions
2022-10-26 – 2024-12-10 · Plaque Psoriasis
What this study did
NCT03536884 · UCB Biopharma SRL
2018-06-13 – 2023-08-09 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
What this study did
NCT03478787 · AbbVie
2018-05-08 – 2020-07-08 · Psoriasis
What this study did
NCT03535194 · Eli Lilly and Company
2018-06-26 – 2020-06-03 · Psoriasis
What this study did
NCT03090100 · Janssen Research & Development, LLC
2017-04-27 – 2018-09-20 · Psoriasis
What this study did
Phase 2 (1)
Psoriasis
NCT03384745 · Bond Avillion 2 Development LP
2018-07-31 – 2020-03-26 · Psoriasis
What this study did
Phase 1 (4)
Psoriasis
NCT06126718 · BioRay Pharmaceutical Co., Ltd.
2024-02-21 – 2024-08-19 · Psoriasis
What this study did
NCT04711343 · Bio-Thera Solutions
2022-06-08 – 2023-06-05 · Psoriasis
What this study did
NCT01828086 · Novartis Pharmaceuticals
2013-06 – 2015-10 · Chronic Plaque-type Psoriasis
What this study did
Other / comorbidity
NCT07054970 · Celltrion
2024-01-12 – 2024-09-06 · Healthy Male Subjects
What this study did
Phase 4 (1)
Hidradenitis Suppurativa
NCT07261072 · Peking Union Medical College
2025-12-01 – 2026-12-31 · Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
What this study did
Appears in other studies (3)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (2)
Psoriasis
NCT07485764 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2026-06 – 2029-06 · Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis, Overweight , Obesity
What this study did
NCT03440736 · Novartis Pharmaceuticals
2018-02-28 – 2022-06-03 · Psoriasis, Metabolic Syndrome
What this study did
Early phase / not applicable (1)
Psoriasis
NCT05503875 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2023-01-01 – 2027-12-31 · Immunoclassification, Psoriasis
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Secukinumab (Cosentyx): this drugApprovedMonoclonal antibodyIL-17Reliable signal
NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002.
NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results).
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3%
NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19%
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results).
NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results).
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002
NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Reliable signal
NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005)
NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001)
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphanot yet graded
NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants
NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Partial signalNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5)
NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo.
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/FPartial signal
NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52).
NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled)
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
VunakizumabPhase 3Monoclonal antibodyIL-17Partial signal
NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively
ZasocitinibPhase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-10374Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(15 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cosentyx (secukinumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
June 2027 (1)
Phase 1Metastatic MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT07237594 · CT.gov ↗
What to watch
August 2027 (1)
Phase 4Ankylosing SpondylitisNot yet recruiting
Est. primary completion 2027-08 · NCT06833112 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2027-12 · NCT04239859 · CT.gov ↗
What to watch
2028 (7)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
February 2028 (1)
Phase 4Non-radiographic Axial SpondyloarthritisActive not recruiting
Est. primary completion 2028-02-08 · NCT05622708 · CT.gov ↗
What to watch
March 2028 (1)
Phase 4PsoriasisRecruiting
Est. primary completion 2028-03-01 · NCT06398106 · CT.gov ↗
What to watch
May 2028 (2)
Phase 3Polymyalgia RheumaticaActive not recruiting
Est. primary completion 2028-05-08 · NCT06331312 · CT.gov ↗
What to watch
Phase 3Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)Recruiting
Est. primary completion 2028-05-15 · NCT07917247 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Axial Spondyloarthritis (AxSpA)Not yet recruiting
Est. primary completion 2028-09-15 · NCT07770646 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Coronary Artery Disease, Hypertension …Not yet recruiting
Est. primary completion 2028-12-31 · NCT07704190 · CT.gov ↗
What to watch
2029 (3)
September 2029 (1)
Phase 4Hidradenitis SuppurativaRecruiting
Est. primary completion 2029-09-25 · NCT07489573 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Takayasu Arteritis, Large Vessel VasculitisNot yet recruiting
Est. primary completion 2029-10-01 · NCT07477795 · CT.gov ↗
What to watch
Phase 1Psoriatic ArthritisRecruiting
Est. primary completion 2029-10-31 · NCT06751238 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 4Autoimmunity, InflammationRecruiting
Est. primary completion 2030-01-29 · NCT04638647 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026ApprovalFDA approves Cosentyx in polymyalgia rheumatica
US, FDA · Source ↗
21 October 2026ApprovalEuropean Commission approves Cosentyx for polymyalgia rheumatica
EU, EC · Source ↗
13 March 2026ApprovalFDA approves Cosentyx for pediatric HS aged 12+
US, FDA · Source ↗
3 July 2025Topline resultPhase III GCAptAIN topline results for Cosentyx in GCA